title: Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
abstract: OBJECTIVE
  To assess the appropriateness of nonsteroidal anti-inflammatory drug (NSAID) use relative to recent osteoarthritis treatment guidelines from the Second Canadian Consensus Conference.
  
  
  METHODS
  Observational study of self-reported practice in a cohort of physicians from the Canadian Osteoarthritis Rx (CANOAR) study.
  
  
  METHODS
  Ontario primary care physicians were recruited from the top 10% of NSAID prescribers based on the number of NSAID prescriptions filled per year. Physicians were asked to record office visits on a 1-page data collection form from November 2000 to December 2001.
  
  
  RESULTS
  Of 1400 physicians invited, 185 were enrolled and 119 registered office visits. Data were analyzed for the first visits of 5459 patients for whom a prescribed NSAID was identified, of whom 60% were female and 46% were older than 65 years. Coxibs were prescribed for 56% of study patients and were more commonly used by those with recent gastrointestinal (GI) events (85%), those receiving warfarin sodium therapy (79%), and those with congestive heart failure (68%). Coxib use increased with increasing global assessment of OA severity, but not patient age. Overall, 58% of prescriptions were considered appropriate given patient GI risk factors.
  
  
  CONCLUSIONS
  Most coxib and NSAID prescriptions were consistent with the guidelines, but there was considerable underuse of coxibs in at-risk patients and some overuse of coxibs and of gastroprotective agents with NSAIDs in patients with no identified GI risk factors. Increased recognition of relationships between patient age and NSAID-related GI risk would likely promote more appropriate use of traditional NSAIDs, coxibs, and gastroprotective agents in osteoarthritis patients.
authors.affiliation: Centre for Evaluation of Medicines, St Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada. sebaldt@mcmaster.ca
authors.forename: Rolf J
authors.initials: RJ
authors.lastname: Sebaldt
authors.forename: Annie
authors.initials: A
authors.lastname: Petrie
authors.forename: Charles H
authors.initials: CH
authors.lastname: Goldsmith
authors.forename: Michael A
authors.initials: MA
authors.lastname: Marentette
mesh_terms: D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D000075202:Contraindications; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000592:standards; D004363:Drug Utilization / Q000592:standards / Q000706:statistics & numerical data*; D005194:Family Practice / Q000592:standards*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D019370:Observation; D009864:Ontario; D010003:Osteoarthritis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000706:statistics & numerical data*; D012307:Risk Factors
chemical_list: D000863:Antacids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors